EvokAI Creative Labs Inc. announced that its latest technology "MDM Flex Sensor" has received the CE Mark approval, a significant milestone that paves the way for further advancements in the field of movement disorder monitoring. The integration of this micro sensor into the EvokAI Movement Disorder Monitor ("MDM") is poised to revolutionize patient care and significantly improve their quality of life. Key Features of this major achievement: CE mark approval is a rigorous process that demonstrates the product's compliance with European Union health and safety standards.

This certification enhances EvokAI's credibility and builds trust with customers, healthcare professionals, and regulatory authorities. With access to the European Economic Area ("EEA") market and enhanced credibility, EvokAI expects increased sales and revenue. Healthcare providers and institutions purchase and implement technology that meets regulatory standards.

MDM Flex Sensor offers a comprehensive and precise assessment of movement disorders, enabling healthcare professionals to monitor patients' progress with unparalleled accuracy. With real-time data on patients' responses to medication, physicians can create personalized treatment plans that maximize the effectiveness of their interventions. Patients can experience enhanced quality of life as their treatments become more tailored to their specific needs, minimizing side effects and optimizing symptom control.

Generally, any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "ex expects", or " does not expect", "anticipates" or " does not anticipate", "budget", "scheduled", "forecasts", "estimates", "bel believes" or "intends" or "intends" and variations of such words and phrases or stating that certain actions, events or results " may" or " could", "would", " might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information or statements. These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements.

Such factors, among other things, include: business integration risks; fluctuations in general macroeconomic conditions; fluctuations in securities markets; the Company's limited operating history; future capital needs and uncertainty of additional financing; the competitive nature of the technology industry; unproven markets for the Company's product offerings; lack of regulation and customer protection; the need for the Company to manage its planned growth and expansion; the effects of product development and need for continued technology change; protection of proprietary rights; network security risks; the ability of the Company to maintain properly working systems; foreign currency trading risks; use and storage of personal information and compliance with privacy laws; use of the Company's services for improper or illegal purposes; global economic and financial market conditions; uninsurable risks; changes in project parameters as plans continue to be evaluated; and those factors described under the heading "R risks" in the Company's filing statement dated March 27, 2023 available on SEDAR. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. According to the Company's technology has the potential to transform the way movement disorders are diagnosed, or advanced sensor fusion, the Company's market reach in Europe while prepare to bring the technology to the U.S. market.